Oppenheimer Holdings, Inc. Reiterates Buy Rating for United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (NASDAQ:UTHR)‘s stock had its “buy” rating reissued by Oppenheimer Holdings, Inc. in a research report issued on Friday.

Other equities research analysts have also recently issued research reports about the stock. ValuEngine cut shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 2nd. BidaskClub cut shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Zacks Investment Research cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. UBS AG reissued a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Finally, Jefferies Group LLC reissued a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, June 8th. Six analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the stock. United Therapeutics Corporation currently has a consensus rating of “Hold” and an average target price of $134.50.

Shares of United Therapeutics Corporation (UTHR) traded down 0.29% during trading on Friday, reaching $120.47. 431,185 shares of the company were exchanged. The stock has a 50-day moving average price of $130.11 and a 200-day moving average price of $130.47. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89. The stock has a market capitalization of $5.23 billion, a PE ratio of 13.97 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.61 by $4.86. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The business had revenue of $444.60 million during the quarter, compared to analysts’ expectations of $391.53 million. During the same period last year, the company posted $4.42 EPS. United Therapeutics Corporation’s revenue for the quarter was up 7.8% on a year-over-year basis. Analysts forecast that United Therapeutics Corporation will post $10.09 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was first reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.themarketsdaily.com/2017/09/11/oppenheimer-holdings-inc-reiterates-buy-rating-for-united-therapeutics-corporation-uthr.html.

In other news, CEO Martine A. Rothblatt sold 1,238 shares of the firm’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $130.20, for a total value of $161,187.60. Following the completion of the sale, the chief executive officer now directly owns 1,378 shares of the company’s stock, valued at approximately $179,415.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 1,232 shares of the firm’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $133.32, for a total transaction of $164,250.24. Following the completion of the sale, the chief executive officer now directly owns 2,301 shares of the company’s stock, valued at $306,769.32. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 25,178 shares of company stock valued at $3,289,427. Corporate insiders own 7.80% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. HPM Partners LLC increased its stake in shares of United Therapeutics Corporation by 0.8% in the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after acquiring an additional 15 shares in the last quarter. First Allied Advisory Services Inc. increased its stake in shares of United Therapeutics Corporation by 0.4% in the 2nd quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock worth $598,000 after acquiring an additional 19 shares in the last quarter. Nomura Asset Management Co. Ltd. increased its stake in shares of United Therapeutics Corporation by 0.3% in the 1st quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock worth $1,712,000 after acquiring an additional 40 shares in the last quarter. Fisher Asset Management LLC increased its stake in shares of United Therapeutics Corporation by 1.4% in the 2nd quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock worth $411,000 after acquiring an additional 45 shares in the last quarter. Finally, Argent Capital Management LLC increased its stake in shares of United Therapeutics Corporation by 2.4% in the 1st quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock worth $343,000 after acquiring an additional 60 shares in the last quarter.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply